Log in to save to my catalogue

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treate...

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treate...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2446966114

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

About this item

Full title

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Publisher

England: Elsevier Ltd

Journal title

The lancet oncology, 2020-10, Vol.21 (10), p.1353-1365

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

SummaryBackgroundTumour mutational burden (TMB) has been retrospectively correlated with response to immune checkpoint blockade. We prospectively explored the association of high tissue TMB (tTMB-high) with outcomes in ten tumour-type-specific cohorts from the phase 2 KEYNOTE-158 study, which assessed the anti-PD-1 monoclonal antibody pembrolizumab...

Alternative Titles

Full title

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2446966114

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2446966114

Other Identifiers

ISSN

1470-2045

E-ISSN

1474-5488

DOI

10.1016/S1470-2045(20)30445-9

How to access this item